Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications

Julie A. Campbell (), Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid Mei and Andrew J. Palmer ()
Additional contact information
Julie A. Campbell: Menzies Institute for Medical Research, University of Tasmania
Glen J. Henson: Menzies Institute for Medical Research, University of Tasmania
Valery Fuh Ngwa: Menzies Institute for Medical Research, University of Tasmania
Hasnat Ahmad: Menzies Institute for Medical Research, University of Tasmania
Bruce V. Taylor: Menzies Institute for Medical Research, University of Tasmania
Ingrid Mei: Menzies Institute for Medical Research, University of Tasmania
Andrew J. Palmer: Menzies Institute for Medical Research, University of Tasmania

PharmacoEconomics, 2025, vol. 43, issue 2, No 8, 223-239

Abstract: Abstract Background Multiple sclerosis (MS) is a chronic autoimmune/neurodegenerative disease associated with progressing disability affecting mostly women. We aim to estimate transition probabilities describing MS-related disability progression from no disability to severe disability. Transition probabilities are a vital input for health economics models. In MS, this is particularly relevant for pharmaceutical agency reimbursement decisions for disease-modifying therapies (DMTs). Methods Data were obtained from Australian participants of the MSBase registry. We used a four-state continuous-time Markov model to describe how people with MS transition between disability milestones defined by the Expanded Disability Status Scale (scale 0–10): no disability (EDSS of 0.0), mild (EDSS of 1.0–3.5), moderate (EDSS of 4.0–6.0), and severe (EDSS of 6.5–9.5). Model covariates included sex, DMT usage, MS-phenotype, and disease duration, and analysis of covariate groups were also conducted. All data were recorded by the treating neurologist. Results A total of N = 6369 participants (mean age 42.5 years, 75.00% female) with 38,837 person-years of follow-up and 54,570 clinical reviews were identified for the study. Annual transition probabilities included: remaining in the no, mild, moderate, and severe states (54.24%, 82.02%, 69.86%, 77.83% respectively) and transitioning from no to mild (42.31%), mild to moderate (11.38%), and moderate to severe (9.41%). Secondary-progressive MS was associated with a 150.9% increase in the hazard of disability progression versus relapsing–remitting MS. Conclusions People with MS have an approximately 45% probability of transitioning from the no disability state after one year, with people with progressive MS transitioning from this health state at a much higher rate. These transition probabilities will be applied in a publicly available health economics simulation model for Australia and similar populations, intended to support reimbursement of a plethora of existing and upcoming interventions including medications to reduce progression of MS.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-024-01417-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:2:d:10.1007_s40273-024-01417-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-024-01417-4

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().